Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event

Rhea-AI Summary

LARIMAR Therapeutics, Inc. (Nasdaq: LRMR) announced participation in 1x1 investor meetings at the SVB Leerink CybeRx Series event focused on neuromuscular and rare diseases, scheduled for September 22-23, 2021. Larimar is a clinical-stage biotech company dedicated to developing treatments for complex rare diseases, with its lead compound, CTI-1601, undergoing Phase 1 clinical trials as a potential treatment for Friedreich's ataxia. The company aims to leverage its innovative intracellular delivery platform for future therapies targeting additional rare diseases.

BALA CYNWYD, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in 1x1 investor meetings at the SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1x1 Event. The event is taking place virtually September 22-23, 2021.

About Larimar Therapeutics

Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the U.S. as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569

Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715

FAQ

What is Larimar Therapeutics' focus in biotechnology?

Larimar Therapeutics focuses on developing treatments for complex rare diseases.

What is the significance of Larimar's compound CTI-1601?

CTI-1601 is Larimar's lead compound currently in Phase 1 trials as a potential treatment for Friedreich's ataxia.

When is the SVB Leerink CybeRx Series event taking place?

The SVB Leerink CybeRx Series event is scheduled for September 22-23, 2021.

How is Larimar Therapeutics participating in the SVB Leerink event?

Larimar Therapeutics will participate in 1x1 investor meetings during the SVB Leerink event.

What platform does Larimar plan to use for developing new therapies?

Larimar plans to use its intracellular delivery platform to design fusion proteins targeting rare diseases.